Xiwang Biotechnology (Suzhou) Co., Ltd. – Trademark Portfolio
Entity Type: 16
Xiwang Biotechnology (Suzhou) Co., Ltd. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 18 filings in this category. Currently, 14 trademarks are registered and 1 is pending. Notable registered marks include EELSTIDE, PEPERWHI, SUPLOQUA, YOUBLICA, and BESCATHIN. The owner is based in Suzhou, Jiangsu.
Room 406, 4th Floor, Building 1, Ideal Innovation Building, No. 69 Jiuzhang Road
Suzhou, Jiangsu 215000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Xiwang Biotechnology (Suzhou) Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Xiwang Biotechnology (Suzhou) Co., Ltd. have?
Xiwang Biotechnology (Suzhou) Co., Ltd. has 18 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 pending, 2 abandoned.
What trademark classes does Xiwang Biotechnology (Suzhou) Co., Ltd. file in?
Xiwang Biotechnology (Suzhou) Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Xiwang Biotechnology (Suzhou) Co., Ltd.'s most well-known trademarks?
Xiwang Biotechnology (Suzhou) Co., Ltd.'s registered trademark portfolio includes well-known marks such as EELSTIDE, PEPERWHI, SUPLOQUA, YOUBLICA, and BESCATHIN. These are among 14 currently registered trademarks in the portfolio.
What is Xiwang Biotechnology (Suzhou) Co., Ltd.'s trademark registration success rate?
Xiwang Biotechnology (Suzhou) Co., Ltd. has a 88% trademark registration rate, with 14 out of 16 resolved applications resulting in successful registration. Currently, 1 application is pending review.